Australia's most trusted
source of pharma news
Friday, 12 December 2025
Posted 12 December 2025 AM
AI analysis has given new hope to a drug that showed no efficacy in a Phase 2 trial, with plans underway to launch a more targeted study.
In September Perth-based Argenica released results of a Phase 2 trial which showed its drug ARG-007 was safe, which was the primary endpoint, but also that it had no overall treatment effect compared to a placebo. That saw it lose more than half of its share price.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.